At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals. This week on “The Top Line,” Fierce Pharma’s Eric Sagonowsky and Kevin Dunleavy, both instrumental in creating the special report, are breaking down the numbers and sharing key insights into the landscape of drug approvals in 2023.
To learn more about the topics in this episode:
- 2023 drug approvals: After a down year, FDA signs off on a bounty of new meds, including 7 from Pfizer
- 2022 drug approvals: After Aduhelm fiasco, FDA endorsements drop to 37
- 2021 drug approvals: In a year dominated by COVID, biopharma managed to deliver 55 new drugs